Sign in Subscribe
Class action lawsuits

Rocket Pharmaceuticals, Inc. Faces Class Action Lawsuit Over Securities Fraud Allegations

Strategic Insights

— 1 min read

A class action securities lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) alleging securities fraud between September 17, 2024, and May 26, 2025. The lawsuit claims that the company made false and misleading statements to investors about the safety and clinical trial protocol of its RP-A501 treatment, which led to a significant decline in stock price.

According to the complaint, Rocket Pharmaceuticals provided overly positive statements to investors while concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol. The company allegedly failed to disclose critical updates to shareholders, including the introduction of a novel immunomodulatory agent to the pretreatment regimen, which led to the death of participants enrolled in the study. This information was not disclosed until May 27, 2025, when the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE).

The price of Rocket's common stock plummeted following this news, declining by approximately 37% in a single trading day, from $6.27 to $2.33 per share. The lawsuit seeks to recover losses incurred by shareholders who were affected by these alleged securities fraud actions.

Key Takeaways:

  • Rocket Pharmaceuticals, Inc. faces a class action lawsuit alleging securities fraud between September 17, 2024, and May 26, 2025.
  • The lawsuit claims that the company made false and misleading statements about the safety and clinical trial protocol of its RP-A501 treatment.
  • The company allegedly failed to disclose critical updates to shareholders, including the introduction of a novel immunomodulatory agent to the pretreatment regimen.
  • The FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event.
  • The price of Rocket's common stock declined significantly, plummeting approximately 37% in a single trading day.
  • The lawsuit seeks to recover losses incurred by shareholders who were affected by these alleged securities fraud actions.

Statistics:

  • $6.27: Closing market price of Rocket's common stock on May 23, 2025.
  • $2.33: Closing market price of Rocket's common stock on May 27, 2025.
  • 37%: Decline in Rocket's common stock price in a single trading day (May 23-27, 2025).

Sources:

  • Newsfile Corp. - August 5, 2025
  • Levi & Korsinsky, LLP

Read more